Clinical hold
Nurixâs B-cell cancer drug on partial hold by FDA over manufacturing issues
Anika Sharma
Nurix Therapeutics has temporarily halted a phase 1 trial for its B-cell malignancy drug, NX-2127, as it undertakes a manufacturing ...
Innate Pharma halts lymphomas trials after patient death, but key study continues
Anika Sharma
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...
Hemogenyx clears FDA hurdle for its novel CAR-T therapy for AML
Anika Sharma
Hemogenyx Pharmaceuticals has moved a step closer to advancing its CAR-T therapy, HEMO-CAR-T, into clinical trials following the FDA’s acceptance ...
Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold
Anika Sharma
Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...
